Severance Agreements in the Biotechnology Industry
437 Contracts & Agreements
- 2seventy bio, Inc. (1 contract)
- Achaogen, Inc. (1)
- Acorda Therapeutics (1)
- Adamas Pharmaceuticals Inc (3)
- Adaptimmune Therapeutics PLC (4)
- ADURO BIOTECH, INC. (7)
- Aeglea BioTherapeutics, Inc. (10)
- AGIOS PHARMACEUTICALS INC (2)
- AILERON THERAPEUTICS INC (6)
- AKCEA THERAPEUTICS, INC. (9)
- Akebia Therapeutics, Inc. (3)
- ALBIREO PHARMA, INC. (2)
- Alliqua BioMedical, Inc. (4)
- Amgen Inc. (1)
- Aprea Therapeutics, Inc. (2)
- Aptevo Therapeutics Inc. (2)
- Aravive, Inc. (3)
- Arbutus Biopharma Corp (2)
- ARCA biopharma, Inc. (1)
- Arcturus Therapeutics Holdings Inc. (1)
- Arcus Biosciences, Inc. (1)
- ARENA PHARMACEUTICALS INC (15)
- ARROWHEAD PHARMACEUTICALS, INC. (4)
- ARYA Sciences Acquisition Corp II (3)
- ATOSSA GENETICS INC (1)
- Aura Biosciences, Inc. (1)
- Avid Bioservices, Inc. (2)
- BioAtla, Inc. (4)
- BIOCRYST PHARMACEUTICALS INC (1)
- Biogen Inc. (14)
- BIOMARIN PHARMACEUTICAL INC (8)
- Bolt Biotherapeutics, Inc. (1)
- Calithera Biosciences, Inc. (2)
- Calyxt, Inc. (4)
- CATABASIS PHARMACEUTICALS INC (2)
- Cellular Biomedicine Group, Inc. (2)
- CHIMERIX INC (5)
- CLEVELAND BIOLABS INC (1)
- Codiak BioSciences, Inc. (1)
- Conatus Pharmaceuticals Inc. (1)
- Cortexyme, Inc. (2)
- CTI BIOPHARMA CORP (13)
- Cyclerion Therapeutics, Inc. (2)
- Cytokinetics, Incorporated (1)
- CYTORI THERAPEUTICS, INC. (5)
- Diffusion Pharmaceuticals Inc. (1)
- DYNAVAX TECHNOLOGIES CORP (11)
- Dyne Therapeutics, Inc. (1)
- Eagle Pharmaceuticals, Inc. (3)
- Editas Medicine, Inc. (3)
- Emergent BioSolutions Inc. (2)
- ENZON PHARMACEUTICALS, INC. (6)
- ESSA Pharma Inc. (0)
- Evelo Biosciences, Inc. (3)
- EXACT SCIENCES CORP (1)
- FIVE PRIME THERAPEUTICS INC (17)
- FS Development Corp. II (1)
- Generation Bio Co. (1)
- GERON CORP (5)
- Gilead Sciences (14)
- Graphite Bio, Inc. (1)
- HALOZYME THERAPEUTICS INC (4)
- HEAT BIOLOGICS, INC. (3)
- iBio, Inc. (1)
- IMMUCELL CORP (1)
- IMMUNE PHARMACEUTICALS INC (1)
- IMMUNOGEN INC (18)
- INFINITY PHARMACEUTICALS, INC. (2)
- INOVIO PHARMACEUTICALS, INC. (4)
- INSMED Inc (2)
- IO Biotech, Inc. (1)
- IONIS PHARMACEUTICALS INC (2)
- IOVANCE BIOTHERAPEUTICS, INC. (2)
- IRONWOOD PHARMACEUTICALS INC (6)
- Isoray, Inc. (1)
- Karyopharm Therapeutics Inc. (2)
- Kindred Biosciences, Inc. (1)
- LEXICON PHARMACEUTICALS, INC. (2)
- Ligand Pharmaceuticals Incorporated (4)
- Lyell Immunopharma, Inc. (3)
- MAXCYTE, INC. (7)
- MEDICINOVA INC (11)
- Metacrine, Inc. (1)
- MiMedx Group, Inc. (1)
- Mirati Therapeutics, Inc. (1)
- Mirum Pharmaceuticals, Inc. (2)
- Moderna, Inc. (1)
- Morphic Holding, Inc. (1)
- Natera, Inc. (1)
- Nkarta, Inc. (1)
- NTN BUZZTIME INC (2)
- Ophthotech Corp. (1)
- Opko Health, Inc. (1)
- PDL BIOPHARMA, INC. (6)
- PhaseBio Pharmaceuticals Inc (2)
- PIERIS PHARMACEUTICALS, INC. (2)
- PORTOLA PHARMACEUTICALS INC (2)
- PROGENITY, INC. (2)
- Protagonist Therapeutics, Inc (9)
- Prothena Corp plc (3)
- Radius Health, Inc. (7)
- Reneo Pharmaceuticals, Inc. (4)
- Replimune Group, Inc. (1)
- RIGEL PHARMACEUTICALS INC (5)
- SANGAMO THERAPEUTICS, INC (2)
- Sarepta Therapeutics, Inc. (2)
- Savara Inc (7)
- SEATTLE GENETICS INC (3)
- SELLAS Life Sciences Group, Inc. (1)
- Sigilon Therapeutics, Inc. (2)
- SUNESIS PHARMACEUTICALS INC (16)
- Synthetic Biologics, Inc. (1)
- TENAX THERAPEUTICS, INC. (1)
- Tracon Pharmaceuticals, Inc. (9)
- Trovagene, Inc. (1)
- Turning Point Therapeutics, Inc. (6)
- VACCINEX, INC. (1)
- Vaxart, Inc. (6)
- VICAL INC (3)
- Viela Bio, Inc. (1)
- VITAL THERAPIES INC (1)
- Xencor Inc (6)
- Y-mAbs Therapeutics, Inc. (1)
- ZIOPHARM ONCOLOGY INC (2)
- Chimerix, Inc. Amended and Restated Officer and Severance Benefit Plan (CHIMERIX INC, Filed With SEC on November 14, 2024)
- Gilead Sciences, Inc. Severance Plan, amended and restated (Gilead Sciences, Filed With SEC on November 12, 2024)
- Executive Severance Plan for Chief-Level Executives (Replimune Group, Inc., Filed With SEC on November 12, 2024)
- Executive Severance Plan, and form of participation agreement thereunder (Aura Biosciences, Inc., Filed With SEC on November 12, 2024)
- Severance Agreement and General Release dated as of August 2, 2024, between Ligand Pharmaceuticals Incorporated and Mr. Korenberg (Ligand Pharmaceuticals Incorporated, Filed With SEC on November 8, 2024)
- Confidential Severance Agreement and General Release, effective as of October 9, 2024, by and between Aprea Therapeutics, Inc. and Nadeem Q. Mirza, M.D., M.P.H (Aprea Therapeutics, Inc., Filed With SEC on November 7, 2024)
- Severance Agreement, dated May 22, 2020, by and between Kathleen Goin and Palvella Therapeutics, Inc (PIERIS PHARMACEUTICALS, INC., Filed With SEC on August 9, 2024)
- Severance Agreement, dated May 22, 2020, by and between Kathleen A. McGowan and Palvella Therapeutics, Inc (PIERIS PHARMACEUTICALS, INC., Filed With SEC on August 9, 2024)
- Executive Severance Policy of Adaptimmune Therapeutics plc dated March 10, 2017 and amended and restated effective as of June 11, 2024 and on July 16, 2024 (Adaptimmune Therapeutics PLC, Filed With SEC on July 16, 2024)
- Executive Severance Policy of Adaptimmune Therapeutics plc dated March 10, 2017 and amended and restated effective as of June 11, 2024 (Adaptimmune Therapeutics PLC, Filed With SEC on June 11, 2024)
- iBio, Inc. Officer Severance Benefit Plan, effective May 9, 2024 (iBio, Inc., Filed With SEC on May 13, 2024)
- Executive Severance Plan (Natera, Inc., Filed With SEC on May 10, 2024)
- Severance Agreement dated March 21, 2024 between Y-mAbs Therapeutics A/S and Steen Lisby (Y-mAbs Therapeutics, Inc., Filed With SEC on May 7, 2024)
- Form of Officer Executive Severance Agreement (Reflecting Clawback Policy) (Akebia Therapeutics, Inc., Filed With SEC on March 14, 2024)
- Participation Agreement under Severance Plan for Michael Sumner (INOVIO PHARMACEUTICALS, INC., Filed With SEC on March 6, 2024)
- Participation Agreement under Severance Plan for Laurent Humeau (INOVIO PHARMACEUTICALS, INC., Filed With SEC on March 6, 2024)
- Participation Agreement under Severance Plan for Jacqueline Shea (INOVIO PHARMACEUTICALS, INC., Filed With SEC on March 6, 2024)
- Inovio Pharmaceuticals, Inc. Severance Plan and Summary Plan Description (INOVIO PHARMACEUTICALS, INC., Filed With SEC on March 6, 2024)
- Severance Benefits Policy for Senior Vice Presidents and Vice Presidents (ARYA Sciences Acquisition Corp II, Filed With SEC on February 27, 2024)
- Severance Benefits Policy for Specified C-Suite Executives (ARYA Sciences Acquisition Corp II, Filed With SEC on February 27, 2024)
- Arcus Biosciences, Inc. Severance Benefits Plan (Arcus Biosciences, Inc., Filed With SEC on February 21, 2024)
- Severance Policy (HALOZYME THERAPEUTICS INC, Filed With SEC on February 20, 2024)
- Severance Agreement, between the registrant and Cenk Sumen (MAXCYTE, INC., Filed With SEC on January 26, 2024)
- Form of Severance Agreement (Aeglea BioTherapeutics, Inc., Filed With SEC on December 22, 2023)
- Amended and Restated Severance Benefits Plan (Editas Medicine, Inc., Filed With SEC on November 22, 2023)
- Form of Severance Agreement (Aeglea BioTherapeutics, Inc., Filed With SEC on November 15, 2023)
- Severance agreement between the Registrant and Eva Ehrnrooth, dated August 10, 2023 (IO Biotech, Inc., Filed With SEC on November 13, 2023)
- Executive Severance Plan, as amended (RIGEL PHARMACEUTICALS INC, Filed With SEC on November 7, 2023)
- Severance Policy for Senior Vice Presidents and Vice Presidents, dated October 11, 2022, by and between Mirati Therapeutics, Inc. and Aaron A. Ondrey (Mirati Therapeutics, Inc., Filed With SEC on November 6, 2023)
- Cytokinetics, Incorporated Executive Severance Plan and Summary Plan Description (Cytokinetics, Incorporated, Filed With SEC on October 3, 2023)
- Mirum Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan and form of Participation Agreement thereunder (Mirum Pharmaceuticals, Inc., Filed With SEC on August 30, 2023)
- Form of Management Continuity and Severance Agreement between Company and certain of its executive officers (DYNAVAX TECHNOLOGIES CORP, Filed With SEC on August 3, 2023)
- Second Amendment to Calyxts 2021 Executive Severance Plan (Calyxt, Inc., Filed With SEC on May 17, 2023)
- Amendment No. 2 to Severance Agreement by and between James Fong and CTI BioPharma Corp (CTI BIOPHARMA CORP, Filed With SEC on May 15, 2023)
- Severance Agreement, dated March 27, 2023, by and between the Registrant and Robert Francomano (SELLAS Life Sciences Group, Inc., Filed With SEC on May 11, 2023)
- Amendment to the Vaxart, Inc. Severance Benefit Plan dated May 2, 2023 (Vaxart, Inc., Filed With SEC on May 4, 2023)
- Confidential Severance Agreement and General Release between Aprea Therapeutics, Inc. and Scott M. Coiante (Aprea Therapeutics, Inc., Filed With SEC on March 30, 2023)
- Severance Agreement, dated March 27, 2023, by and between the registrant and Douglas J. Swirsky (MAXCYTE, INC., Filed With SEC on March 28, 2023)
- Severance Agreement between Globalization Partners Switzerland SA and Nicola Heffron, dated February 17, 2023 (2seventy bio, Inc., Filed With SEC on March 16, 2023)
- Severance Agreement, dated February 13, 2023, by and between Evelo Biosciences, Inc. and Jonathan Zung (Evelo Biosciences, Inc., Filed With SEC on March 16, 2023)
